Jeffrey Church
Director of Finance/CFO at IMUNON, INC.
Net worth: 5 208 $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stacy Lindborg | M | 53 | 3 years | |
Michael Tardugno | M | 73 | 17 years | |
Christine Pellizzari | F | 56 | 3 years | |
Frederick Fritz | M | 73 | 13 years | |
James Dentzer | M | 57 | 2 years | |
Donald Braun | M | 74 | 9 years | |
Khursheed Anwer | M | 64 | 10 years | |
Kimberly Bragg | F | - | - | |
Sebastien Hazard | M | 53 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bruce Peacock | M | 72 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | - |
Wendy Perrow | F | 66 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 8 years |
Corinne Le Goff | M | 58 | 2 years | |
Wayne T. Hockmeyer | M | 79 | 17 years | |
James Vincent Lambert | M | 60 | 11 years | |
Robert Hooper | M | 77 | 12 years | |
David P. Wright | M | 75 | 1 years | |
John A. Lambert | M | 71 | 3 years | |
Max E. Link | M | 84 | 17 years | |
Thomas H. Fraser | M | - | - | |
William N. Kelley | M | 84 | 15 years | |
Evdoxia E. Kopsidas | F | 59 | 3 years | |
Andreas Voss | M | 65 | 6 years | |
Pok Yu Chow | M | 71 | 16 years | |
Alberto R. Martinez | M | 74 | 10 years | |
Zola P. Horovitz | M | 89 | 11 years | |
Michael Taylor | M | - | 4 years | |
Joshua Ruch | M | 74 | 8 years | |
Raj Prabhakar | M | 50 | 11 years | |
Milan Kovacevic | M | - | - | |
Francisco Leon | M | 52 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 3 years |
Paul Kessler | M | 69 | 7 years | |
Pincus Steven | M | - | - | |
Frank Gary Renshaw | M | - | - | |
Harriet Shelare | F | - | - | |
Thomas Wickham | M | - | 11 years | |
Constantine Kardaras | M | - | - | |
Jason G. Fewell | M | - | 7 years | |
Bryan T. Butman | M | 69 | 18 years | |
Len Stigliano | M | 76 | - | |
Douglas B. Jacoby | M | - | 2 years | |
Herbert Conrad | M | 91 | 7 years | |
Denis M. O'Donnell | M | 70 | 16 years | |
Hal R. Werner | M | 75 | 5 years | |
Thomas Andrew Davis | M | 60 | 1 years | |
Mark Owens Thornton | M | 66 | 4 years | |
Barbara Hackman Franklin | F | 84 | 5 years | |
Gary Pace | M | 76 | 8 years | |
Penny M. Heaton | M | 59 | - | |
Stelios Papadopoulos | M | 75 | 3 years | |
Henrik Rasmussen | M | 65 | 4 years | |
Grant Yonehiro | M | 60 | 6 years | |
Gregory Weaver | M | 68 | 8 years | |
Nita U. Patel | M | 64 | - | |
James M. Robinson | M | - | 3 years | |
Nicholas Borys | M | 64 | 16 years | |
Jim Robinson | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 56 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeffrey Church
- Personal Network